Dynavax to Participate in Upcoming Investor Conferences
Dynavax Technologies (Nasdaq: DVAX), a commercial-stage biopharmaceutical company focused on innovative vaccine development, has announced its participation in two major upcoming investor conferences:
- TD Cowen 45th Annual Healthcare Conference on March 4 at 1:10 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on March 11 at 10:00 a.m. ET
The company will provide webcasted presentations accessible through their investor relations website. Dynavax currently markets two commercial products: HEPLISAV-B vaccine, approved in the U.S., EU, and UK for hepatitis B virus prevention in adults 18+, and CpG 1018 adjuvant, used in HEPLISAV-B and various COVID-19 vaccines.
Dynavax Technologies (Nasdaq: DVAX), un'azienda biofarmaceutica in fase commerciale focalizzata sullo sviluppo di vaccini innovativi, ha annunciato la sua partecipazione a due importanti conferenze per investitori in arrivo:
- 45ª Conferenza Annuale sulla Salute di TD Cowen il 4 marzo alle 13:10 ET
- 27ª Conferenza Annuale Globale sulla Salute di Barclays l'11 marzo alle 10:00 ET
L'azienda fornirà presentazioni in webcast accessibili tramite il loro sito web per le relazioni con gli investitori. Dynavax attualmente commercializza due prodotti: il vaccino HEPLISAV-B, approvato negli Stati Uniti, nell'UE e nel Regno Unito per la prevenzione del virus dell'epatite B negli adulti di età superiore ai 18 anni, e l'adjuvante CpG 1018, utilizzato in HEPLISAV-B e in vari vaccini contro il COVID-19.
Dynavax Technologies (Nasdaq: DVAX), una compañía biofarmacéutica en etapa comercial centrada en el desarrollo de vacunas innovadoras, ha anunciado su participación en dos importantes conferencias para inversores que se avecinan:
- 45ª Conferencia Anual de Salud de TD Cowen el 4 de marzo a la 1:10 p.m. ET
- 27ª Conferencia Global Anual de Salud de Barclays el 11 de marzo a las 10:00 a.m. ET
La compañía ofrecerá presentaciones transmitidas por webcast accesibles a través de su sitio web de relaciones con inversores. Dynavax actualmente comercializa dos productos: la vacuna HEPLISAV-B, aprobada en EE. UU., UE y Reino Unido para la prevención del virus de la hepatitis B en adultos mayores de 18 años, y el adyuvante CpG 1018, utilizado en HEPLISAV-B y en varias vacunas contra el COVID-19.
다이나박스 테크놀로지스 (Nasdaq: DVAX)는 혁신적인 백신 개발에 집중하는 상업 단계의 생명공학 회사로, 다가오는 두 가지 주요 투자자 회의에 참여할 것이라고 발표했습니다:
- TD Cowen 제45회 연례 헬스케어 회의 3월 4일 오후 1:10 ET
- 바클레이스 제27회 글로벌 헬스케어 회의 3월 11일 오전 10:00 ET
회사는 투자자 관계 웹사이트를 통해 접근할 수 있는 웹캐스트 발표를 제공할 것입니다. 다이나박스는 현재 두 가지 상업 제품을 판매하고 있습니다: HEPLISAV-B 백신, 미국, EU 및 영국에서 18세 이상의 성인을 위한 B형 간염 바이러스 예방을 위해 승인되었으며, CpG 1018 보조제는 HEPLISAV-B 및 다양한 COVID-19 백신에 사용됩니다.
Dynavax Technologies (Nasdaq: DVAX), une entreprise biopharmaceutique en phase commerciale axée sur le développement de vaccins innovants, a annoncé sa participation à deux grandes conférences pour investisseurs à venir :
- 45e Conférence Annuelle sur la Santé de TD Cowen le 4 mars à 13h10 ET
- 27e Conférence Annuelle Mondiale sur la Santé de Barclays le 11 mars à 10h00 ET
L'entreprise proposera des présentations en webcast accessibles via son site web de relations avec les investisseurs. Dynavax commercialise actuellement deux produits : le vaccin HEPLISAV-B, approuvé aux États-Unis, dans l'UE et au Royaume-Uni pour la prévention du virus de l'hépatite B chez les adultes de 18 ans et plus, et l'adjuvant CpG 1018, utilisé dans HEPLISAV-B et divers vaccins contre le COVID-19.
Dynavax Technologies (Nasdaq: DVAX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf die Entwicklung innovativer Impfstoffe konzentriert, hat seine Teilnahme an zwei wichtigen bevorstehenden Investorenkonferenzen angekündigt:
- 45. TD Cowen Annual Healthcare Conference am 4. März um 13:10 Uhr ET
- 27. Barclays Annual Global Healthcare Conference am 11. März um 10:00 Uhr ET
Das Unternehmen wird Webcast-Präsentationen anbieten, die über seine Investor Relations-Website zugänglich sind. Dynavax vertreibt derzeit zwei kommerzielle Produkte: den HEPLISAV-B Impfstoff, der in den USA, der EU und dem Vereinigten Königreich zur Prävention des Hepatitis-B-Virus bei Erwachsenen ab 18 Jahren zugelassen ist, und den CpG 1018 Adjuvans, der in HEPLISAV-B und verschiedenen COVID-19-Impfstoffen verwendet wird.
- None.
- None.
- TD Cowen 45th Annual Healthcare Conference on Tuesday, March 4 at 1:10 p.m. ET
- Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11 at 10:00 a.m. ET
The presentations will be webcast and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the
For Investors/Media:
Paul Cox
pcox@dynavax.com
510-665-0499
Nicole Arndt
narndt@dynavax.com
510-665-7264
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-participate-in-upcoming-investor-conferences-302385222.html
SOURCE Dynavax Technologies
FAQ
When is Dynavax (DVAX) presenting at the TD Cowen Healthcare Conference?
What are the main commercial products of Dynavax (DVAX)?
Where is HEPLISAV-B vaccine approved for use?
How can investors access Dynavax's (DVAX) conference presentations?
What is the schedule for Dynavax's (DVAX) Barclays Conference presentation?
